Q-TWiST Analysis Builds on LITESPARK-005 Efficacy of Belzutifan in ccRCC

News
Video

The Q-TWiST analysis from the LITESPARK-005 trial showed statistically significant improvement of belzutifan over everolimus in patients with clear cell RCC.

The enhanced tolerability of belzutifan (Welireg) in patients with clear cell renal cell carcinoma (ccRCC) compared with everolimus (Afinitor) could make it an attractive option for this patient group, according to Thomas Powles, MBBS, MCRP, MD.

Results from the quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of the phase 3 LITESPARK-005 trial (NCT04195750) showed the mean Q-TWiST of 17.47 months in the belzutifan arm and 14.81 months in the everolimus) arm.

The sensitivity analysis assessed grade 1 to 4 serious adverse effects with a mean Q-TWiST of 17.50 months vs 15.03 months in the belzutifan vs everolimus arms, respectively. There was a Q-TWiST gain of 10.50% in this analysis.

CancerNetwork® spoke with Powles, a professor of genitourinary oncology, lead for Solid Tumor Research, and director of Barts Cancer Institute at St. Bartholomew’s Hospital, Queen Mary University of London, regarding these results he presented at the 2025 Kidney Cancer Research Summit (KCRS).

Transcript:

The story behind belzutifan, so far, is an agent that has been developed in 2 areas that are contrasting with each other. No. 1 is VHL-driven disease, and that disease has shown that renal tumors can be put into remission regression associated with belzutifan, preventing surgery on primary renal tumors. That’s important for patients. In the other extreme, in metastatic clear cell renal cancer, we go all the way where it’s been developed very late, third or fourth line, in many cases. Those 2 are very different from each other. The development of the disease, the VHL disease, and how that relates to patients who are very heavily pre-treated, is quite complicated. It’s probable, or even likely, that if we use belzutifan earlier in the disease process, it will work better. What we've shown with this Q-TWiST analysis is not only that it is more active than everolimus, but it appears to be, from a quality-of-life perspective, and a time-dependent quality of life analysis, to be better tolerated, making it an attractive [option].

Reference

Powles T, de Velasco G, Choueiri TK, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005). Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. Abstract 13.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Related Content